Heart failure & cardiomyopathies
Trajectories of Sacubitril/Valsartan Adherence Among Medicare Beneficiaries With Heart Failure
Authors' conclusion
Half of ARNi users were not consistently adherent to the drug in the first year after treatment initiation. There exist significant racial and socioeconomic inequities in longitudinal adherence to ARNi.
Study context
- Population
- Medicare beneficiaries with heart failure (HF) who initiated an angiotensin receptor/neprilysin inhibitor (ARNi) (sacubitril/valsartan), 2015–2018age 77 ± 7 years, 34% female
- Participants
- 9,475 beneficiaries
- Exposure
- Immediate discontinuers vs Early discontinuers vs Late discontinuers vs Intermittently adherent vs Consistently adherent
- Outcome
- Longitudinal ARNi adherence trajectories and factors associated with them
Methodological detailsgroup-based trajectory model, multivariable logistic regression
- Group-based trajectory model
- Multivariable logistic regression
Main finding
As reported in the abstract
ARNi adherence trajectories
Observational data: associations, not effects.
Further findings
Factors associated with nonconsistent adherence
| aOR (95% CI) | ||
|---|---|---|
| County in top 20% of Area Deprivation IndexHigher likelihood of nonconsistent adherence | 1.12 (1.00–1.24) | |
| Black raceHigher likelihood of nonconsistent adherence | 1.36 (1.18–1.56) | |
| Prescriptions from a cardiologistLower likelihood of suboptimal adherence | 0.64 (0.57–0.73) | |
| 0.512Adjusted odds ratio (log scale) |
Original publication
Trajectories of Sacubitril/Valsartan Adherence Among Medicare Beneficiaries With Heart Failure. JACC Adv. Published 8 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →